Object. Genetic mechanisms of atlantoaxial dislocation (AAD) have not previously been elucidated. The authors studied association of polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene, which encodes enzymes of the folate pathway (implicated in causation of neural tube defects [NTDs]), in patients with AAD.
The genetic mechanisms responsible for these disorders have not yet been elucidated. Neural tube defects, another common type of congenital disorder, are also frequently encountered in India, but the incidence of NTDs is very low in developed countries. 11, 13, 14 The specific regional concentration of these two developmental disorders of the spine prompts the question: Could the two disorders have some common genetic basis?
The biological mechanisms underlying developmental anomalies of the spine related to NTDs are due to alterations in the MTHFR gene, the effects of which are to a great extent preventable by periconceptional folate supplementation. 1, 17, 32, 34, [40] [41] [42] Folate serves as a cofactor for enzymes involved in DNA and RNA synthesis and in the supply of methyl groups. 11, 16, 35, 39 The 5,10 MTHFR enzyme helps in catalyzing reduction of 5,10 methylenetetrahydrofolate to 5-methyltetrahydrofolate. Substitution of thymine for cytosine in the MTHFR gene at the 677 bp position (677C→T) results in a thermolabile form of the enzyme that causes a reduced enzymatic activity and, consequently, an elevated plasma homocysteine level. A higher level of homocysteine is postulated to be the causal factor for NTDs. Individuals homozygous or heterozygous for this polymorphism require a dietary folate intake higher than normal to maintain plasma levels of homocysteine. 11, 16, 35 Extrinsic folate supplementation in these cases, therefore, reduces the plasma homocysteine levels without actually altering the polymorphism of the MTHFR gene. Multicentric trials have shown a 70% reduction in the incidence of NTDs with periconceptional folic acid supplementation. 32, 42 Another common polymorphism in the MTHFR gene 1298A→C, (adenine to cytosine substitution) also results in decreased MTHFR activity.
Clinical Material and Methods

Clinical Spectrum
Seventy-five consecutive patients with AAD who underwent surgical intervention at our center were prospectively recruited for the present study. Their age ranged from 4 to 60 years (mean 28.24 Ϯ 10.76 years). Twelve (15.8%) of the patients were younger than 18 years old. There were 55 (73.3%) male and 20 (26.7%) female patients. The patients excluded from the study were those with associated genetic syndromes (such as Down syndrome, Morquio syndrome, and achondroplasia); traumatic AAD; and pain, swelling, and tenderness due to inflammation of diarthrodial joints (as for example, in rheumatoid arthritis).
Radiological Investigations
The radiological investigations included plain dynamic radiography of the CVJ (in neutral position and in flexion and extension) to assess for AAD, the status of the atlas (occipitalized or normal), basilar invagination, and KlippelFeil anomaly. Sagittal and axial T1-and T2-weighted craniospinal MR imaging was performed to assess the extent of cervicomedullary compression, tonsillar herniation, and syringomyelia. 2, 3, 22, 37 Atlantoaxial dislocation was diagnosed on the basis of a minimum atlantodental distance greater than 5 mm for patients younger than 9 years of age and greater than 3 mm for those 9 years or older on lateral radiographs of the CVJ. 2, 26, 37 Based on reducibility of the atlantoaxial joints on flexion-extension movements of the neck, the patients were stratified into two groups: irreducible AAD and reducible AAD. 30 Thus, 66 (88%) patients had irreducible AAD (that is, patients who did not achieve reduction of their AAD on extension or following continuous cervical traction for two weeks) and nine (12%) with reducible AAD (patients in whom AAD was apparent on lateral flexion radiographs of the CVJ and reducible on extension). Basilar invagination was evaluated using the standard craniometric lines. The clinical and radiological findings are summarized in Tables  1 and 2 .
Management of AAD
Patients with reducible AAD were treated with posterior fusion alone (Fig. 1A-D) . In patients with irreducible AAD, cervical traction was applied using Crutchfield tongs, and a single-stage transoral decompression and posterior fusion was performed ( Fig. 2 A-E) . 9, 18, 23, 31 The methods of posterior occipitoatlantoaxial fusion included modified Brooks technique 2, 6 in seven patients; Jain's occipitocervical fusion 21, 22, 24, 37 in 60 patients; and Ransford's contoured rod fusion 28, 36 in eight patients. Thirteen patients with AAD had an associated Chiari malformation Type I. Two of these 13 patients who had reducible AAD underwent a modified Brooks fusion, 2, 6 and the 11 with irreducible AAD underwent either posterior decompression of the rim of the foramen magnum with Jain's occipitocervical fusion (10 patients) 21, 22, 24, 37 or the conventional posterior decompression with duroplasty and Ransford's contoured rod stabilization (one patient).
26,36
Control Group
The control group consisted of 60 age-and sex-matched individuals of the same ethnic group, without any congenital malformation.
Sample Collection and DNA Extraction
Two milliliters of peripheral blood was collected from all individuals who participated in this study, after their consent was obtained. Blood was collected in vials coated with ethylenediaminetetraacetic acid (anticoagulant). The DNA was extracted using the standard phenol-chloroform method and stored in aliquots until required.
Analysis of Polymorphisms
Analysis of MTHFR 677C→T Polymorphism. Determination of the 677C→T MTHFR polymorphism was performed using polymerase chain reaction amplification followed by Hinf I restriction enzyme digestion and detection of the fragments on 3% agarose gel as described by Frosst et al. 16 For amplification, we used the forward primer 5Ј-TGAAGGAGGTGTCTGCGGGA-3Ј and the reverse primer 5Ј-AGGACGGTGCGGTGAGAGTG-3Ј, designed to amplify a 198-bp fragment of the MTHFR gene. Analysis of MTHFR 1298A→C Polymorphism. Determination of the 1298A→C MTHFR polymorphism was carried out by polymerase chain reaction amplification, followed by MboII restriction enzyme digestion and detection of the fragments on 20% polyacrylamide gel as described by van der Put et al. 40 For amplification, we used the forward primer 5Ј-CTTTGGGGAGCTGAAGGACTACTA-3Ј and the reverse primer 5Ј-CACTTTGTGACCATTCCGGTT TG-3Ј, designed to amplify a 163-bp fragment of the MTHFR gene. Restriction enzyme digestion was performed using the MboII restriction enzyme. After overnight digestion, all fragments were resolved on 20% polyacrylamide. The homozygous 1298AA genotype resulted in six fragments of 84, 56, 31, 30, 28, and 18 bp, whereas the homozygous 1298CC resulted in five fragments of 84, 31, 30, 28, and 18 bp. 11 The positive and negative controls for both polymorphisms were sequenced. The genotyping results were independently double scored to ensure accuracy.
Statistical Analysis
Before initiating the study, with the background knowledge of allele frequency, the minimum sample size was calculated using Quanta (version 1.1) software. Thus, 75 patients were recruited for this study to attain sufficient power for possible statistical significance.
The clinical data were analyzed using SPSS 13 software. The chi-square test was used to compare the incidence of variables in the two groups. Genotype and allele frequency were analyzed using the Epi Info (version 3.0; Centers for Disease Control and Prevention) software package. Allele frequencies were deduced from genotype distribution. The Hardy-Weinberg equilibrium was tested in all groups. Statistical significance was accepted at probability values less than 0.05. The ORs as well as their 95% CIs were computed to assess the strength of association, if any, between different genotypes and the subgroups of patients with reducible and irreducible AAD.
We also assessed the overall association of the T allele existing in both the homozygous (TT) and heterozygous (CT) state in patients with AAD. Thus the combined frequency of CT and TT were compared with the frequency of the CC genotype both in the total group and in the subgroup of patients with irreducible AAD. Due to the absence of the TT genotype in the patients with reducible AAD, this comparison was not possible in that subgroup.
Results
The observed frequencies of the various genotypes and alleles of 677C→T and 1298A→C polymorphisms in the MTHFR gene are shown in Table 3 .
Comparison of frequencies of genotypes and alleles in MTHFR 677C→T polymorphisms in patients who have AAD with the frequencies in the control population revealed that the CT genotype frequency was found in 32 (42.7%) of the 75 patients with AAD. This prevalence rate was significantly higher than that in controls with an OR of 3.00 (95% CI 1.28-7.14, p = 0.005). The TT genotype was found only in three patients; hence, valid statistical comparisons could not be performed. The frequency of T alleles was higher in patients with AAD compared with the control group (25.3% compared with 15%; OR 1.92, 95% CI 0.97-3.37, p = 0.053).
Among the 75 patients, 66 had an irreducible AAD; and nine a reducible one. Tables 4 and 5 show the genotype and allele frequencies based on the type of defect in the patients in the two subgroups.
In the subgroup of 66 patients with irreducible AAD, the CT genotype was found in 27 patients (40.9%). This association was statistically significant, with an OR of 2.81 (95% CI 1.17-6.86, p = 0.01). All three of the patients with AAD who had the TT genotype belonged to the irreducible AAD subgroup. Even in this subgroup, valid statistical comparison of the TT genotype with the control population could not be carried out due to the small sample size.
The frequency of the T allele in the irreducible AAD group was also higher (25%) and the OR was high (1.89), but the association was not statistically significant (p = 0.06).
In the subgroup of nine patients with reducible AAD, there was no patient with a TT genotype. The CT genotype was found in five (55.6%) of the nine patients (OR 4.69, 95% CI 0.90-25, p = 0.073). The association with the T allele was not found to be statistically significant, probably due to the small sample size (OR 2.18, 95% CI 0.54-7.54, p = 0.18).
There was no statistically significant difference between the genotype and allele frequency of 1298A→C polymorphism in the overall AAD group or the subgroups in comparison with controls. The comparison of the combined frequency of CT and TT genotypes with the frequency of the CC genotype showed a significant association in both the full AAD group (OR 2.63, 95% CI 1.98-5.90, p = 0.009) and the irreducible AAD subgroup (OR 2.5, 95% CI 1.1-5.74, p = 0.016; Table 6 ).
Discussion
Development of the Spine and CVJ and Literature Review
The CVJ is developmentally one of the most active regions of the spine. 29 The development of the spine is initiated during the gastrulation stage when cells migrating through the primitive streak establish the three-layered embryonic disk. The notochord is formed from midline cells of the disk passing through the primitive node. The overlying ectoderm forms the neural plate, the precursor of the neural tube. The paraxial mesoderm adjacent to the notochord progressively segments into paired somites. The ventromedial parts of the somites, after losing their epithelial structures, form the sclerotomes. In these areas, the cells migrate toward the midline to surround the notochord, forming the perichordal cellular zone. The dense caudal half of the lateral parts of the sclerotome gives rise to the lateral processes and the neural arches of the vertebrae. During the process of resegmentation, halves of two adjacent sclerotomes form a vertebra. The perichordal region shows zones of high and low cell density. The high cell density zone contributes to the formation of intervertebral discs whereas the low density zones develop into the centra of the vertebrae. 12 The first four sclerotomes do not follow this course and fuse to form the occipital bone and the posterior border of the foramen magnum. These four occipital and the first two spinal sclerotomes are responsible for the development of the CVJ. Thus, the first and second occipital sclerotomes form the basiocciput; the third forms the jugular tubercles; and the fourth, or the proatlas, forms the U shape of the foramen magnum, the occipital condyles, the apex of the dens, and the posterior arch and lateral atlantal masses of the atlas. The first spinal sclerotome forms the dens and the anterior and posteroinferior arches of the atlas; the second spinal sclerotome forms the body, facets, and posterior arch of the axis. 30 According to David et al., 12 the developmental fate of the sclerotome cells is specified long before the identity of the individual segments is morphologically apparent and is evidently controlled by a genetic process.
A review of the literature reveals that spinal developmental disorders may often be causally related to genetic defects. 10 In 1967, Gunderson et al. 19 proposed genetic factors for C2-3 (autosomal dominant) and C5-6 (autosomal recessive) fusions. David et al., 12 McGaughran et al., 29 and Károly et al., 25 focused on the genetics of the KFS phenotype. David et al. 12 proposed homeotic transformation due to mutation or disturbed expression of the Hox gene as a possible mechanism responsible for assimilation of the atlas into the occiput. They also proposed that the PAX regulatory genes control segmentation of the somites and sclerotomes to establish vertebral boundaries. 12, 27 During chondrification of the vertebrae, the PAX gene is strongly expressed in the developing vertebrae, and therefore, its expression may underlie vertebral fusion. Together with asymmetrical distribution of the paraxial mesodermal cells and a possible lack of communication across the embryonic midline, this expression could cause asymmetrical fusion patterns. 12, 27 According to Clarke et al., 7, 8 in KFS, the first KFS gene locus identified on chromosome 8 segregates with vertebral fusions. A familial KFS gene locus has also been found on 8q, where an inversion (inv [8] [q22.2q23.3]) has been found segregating with congenital vertebral fusion. 7, 8 On the other hand, the results of a study by Schilgen and Loeser 38 have implicated environmental factors such as alcohol consumption in KFS.
Polymorphisms in various genes have been associated with NTDs and spinal dysraphisms (for example, MTHFR, methionine synthase, and the genes that code for methionine synthase reductase, and cystathione-synthase). 20, 35, 39, 43 
Significance of Association of MTHFR Mutation With AAD
The significantly higher CT genotype frequency of MTHFR 677C→T polymorphism in the total AAD group (OR 3.00, 95% CI 1.28-7.14, p = 0.005) as well as in the irreducible AAD subgroup (OR 2.81, 95% CI 1.17-6.86, p = 0.01) when compared with the control population was an interesting finding. The TT genotype was found only in three patients; hence, valid statistical comparisons could not be performed. All three patients with the TT genotype had irreducible AADs. The frequency of T alleles was higher in patients with AAD compared with the control group (25.3% compared with 15%, respectively; OR 1.92, 95% CI 0.97-3.37, p = 0.053). The comparison of the combined frequency of the CT and TT genotypes with the frequency of the CC genotype again showed a significant association in both the total group of patients with AAD (OR 2.63, 95% CI 1.98-5.90, p = 0.009) and the irreducible AAD subgroup (OR 2.5, 95% CI 1.1-5.74, p = 0.016). This suggests that there is a significant association between AAD, especially the irreducible variety, and both the MTHFR 677C→T polymorphism and a higher T allele frequency, in a situation similar to that seen in patients with NTDs.
This finding has important clinical implications. Neural tube defects have been considerably reduced in the developed countries following institution of periconceptional folic acid supplementation. 1, 32, 34, [40] [41] [42] Selhub et al. 39 observed that 400 g of folic acid is the minimum dose that should be taken periconceptually for preventing NTDs. In the Indian subcontinent, however, and especially in the lower socioeconomic groups, the incidence of NTDs is still high, either because folic acid supplementation has not been provided to mothers during the gestational period or because the doses administered are insufficient. Our findings suggest that perhaps adequate supplementation of periconceptional folic acid to circumvent the effects of missense mutation in the MTHFR gene (677C→T) would not only prevent NTDs from developing but also reduce the incidence of AAD, especially the irreducible variety. Furthermore, they also indicate that the pathogenesis of AAD involves both genetic and nutritional factors, which may explain the clustering of patients in regional areas and especially in the lower socioeconomic strata.
Our present study as well our previously published study comparing the clinicoradiological differences between the reducible and irreducible varieties of AAD have revealed that patients with irreducible AAD have a significantly higher incidence of other congenital radiological markers such as assimilation of the atlas, C2-3 fusion, and occipitoatlantoaxial lateral joint asymmetry than patients with reducible AAD. We had postulated that AAD in the two groups occurred due to differing pathogenetic mechanisms, suggesting that, perhaps, irreducible AAD was due to sclerotomal developmental defects while reducible AAD was due to ligamentous laxity. 37 In the present study, the significant genetic differences in the MTHFR gene mutation between the two subgroups could not be ascertained due to lack of a sufficient sample size of patients in the reducible AAD subgroup. However, the higher (though not statistically significant) incidence of the CT genotype in the reducible AAD subgroup does point to a genetic association in this subgroup also. The MTHFR 1298A→C polymorphism has also been associated with NTDs, 11 but we did not find any significant association of this genotype with AAD.
The 677C→T allele frequency in the control population in our study was 0. 15 15 Lower 677C→T allele frequency has also been reported by authors of other studies performed in India. 14, 33 The higher frequency of the T alleles in our patients with AAD as compared to the Indian control population suggests that the contribution of this MTHFR polymorphism to the genetic etiology of AAD is relatively high.
Study Limitations
This study shows a significant association of the MTHFR 677C→T polymorphism as well as a higher T allele frequency in patients with AAD. Whether the association is causally related is yet to be conclusively established. Perhaps an extensive epidemiological study that notes a decrease in the incidence of AAD following folic acid supplementation, as has been observed for NTDs, may lend credibility to our hypothesis.
Apart from the MTHFR gene, there are many other genetic markers responsible for the maintenance of the enzymatic pathway in folic acid metabolism as well as in the other important steps of spinal development. Evaluation of the relative contributions of mutations in one or more of these steps towards the development of AAD would only be possible with a complex microarray analysis of the patient genome and is much beyond the scope of the present study.
The higher 677C→T allele mutation frequency in the patients in our study was statistically significant in comparison with our control group. This frequency range would have been within normal limits of the control groups reported in the Western literature. The reason for significance in our study was that the control group in the present study as well as in the other studies reported from the Indian subcontinent showed consistently lower levels of the 677C→T frequency when compared with the other ethnic populations. Therefore, more studies would be required in other ethnic groups to conclusively implicate the higher 677C→T mutation frequency in the genesis of AAD.
A missense mutation in the MTHFR gene (677C→T, cytosine→thymine substitution) results in a thermolabile form of the enzyme that causes a reduced enzymatic activity and, consequently, an elevated plasma homocysteine level. The presence of increased plasma homocysteine levels in patients with AAD at an early phase of their lives would conclusively establish the cause-and-effect relationship between impaired folic acid metabolic pathways and AAD. Documenting such a phenomenon, however, is extremely difficult in practical application. The mean age of patients at presentation in our study was 28.24 Ϯ 10.76 years; although AAD probably existed since birth in these patients, it could only be detected subsequent to the development of myelopathy later in life. In infancy and childhood, when the plasma homocysteine levels would presumably be high, it would be difficult to pick up early cases by radiological screening for AAD due to lack of complete osseous ossification at the CVJ.
Conclusions
The MTHFR 677C→T polymorphism as well as a higher T allele frequency have a significant association with AAD, especially the irreducible variety, in a situation similar to that seen in patients with NTDs. Perhaps adequate supplementation of periconceptional folic acid to circumvent the effects of missense mutation in the MTHFR gene 677C→T (as is done for prevention of neural tube defects) would also reduce the incidence of AAD.
